Collaborations, business transactions, agreements & start-ups
From joining forces with established entities to emerging start-ups, we collaborate across the spectrum to bring disruptive health care technologies and novel business ventures to life for the benefit of patients everywhere.
Below is a small sampling.
Mayo Clinic entered into a collaboration with Adaptive Phage Therapeutics, a clinical-stage biotechnology company, to conduct a clinical trial using PhageBank™ investigational therapy to address the need for alternative treatments for chronic infections following joint replacement.
Read more
Anumana, an AI-driven company born from nference and Mayo Clinic, is working to create and bring to market innovative digital sensor diagnostics by applying nference’s AI to Mayo Clinic's deep repository of medical data, providing early diagnosis and intervention to patients.
Read more
Mayo Clinic and W. L. Gore & Associates Inc., a global materials science company, formed a strategic collaboration to advance the development of implantable cell therapies to treat debilitating conditions that have no cure. Avobis Bio - the strategic collaboration - combines Mayo Clinic's clinical and cell expertise and Gore's expertise in material sciences to address some of the most challenging medical issues.
Read more
Mayo Clinic entered into a collaboration with BioSig Technologies, a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, to develop a next-generation AI- and machine learning-powered software for its PURE EP™ system.
Mayo Clinic formed a collaboration with Broad Institute of MIT and Harvard, a research organization that convenes a community of researchers from across many disciplines and partner institutions, to bring COVID-19 testing capabilities and capacity to Mayo Clinic Laboratory clients.
Delta Air Lines collaborated with Mayo Clinic to assess, design and test ways to enhance the travel experience for its customers and employees during the COVID-19 pandemic. Using passenger and community risk models generated through data and analytics alongside general COVID-19 prevention practices, Mayo Clinic experts advised the airline on the development of an employee testing program and operational protocols to reduce the transmission of COVID-19 in the airport and onboard.
Read more
Mayo Clinic and Google announced a 10-year strategic partnership in September 2019 to redefine how health care is delivered and accelerate the pace of health care innovation through digital technologies. Mayo Clinic will transform the way it advances virtual care with AI-enabled digital diagnostics and will leverage Google technology to boost its ability to conduct medical research.
Read more
Mayo Clinic entered into a know-how license agreement with Karkinos, a technology-driven, oncology-focused health care platform. Mayo Clinic is providing knowledge and expertise as the company works to develop a tech-enabled distributed cancer care network in India.
Marani Health, an AI-powered platform for remote pregnancy care co-founded by Mayo Clinic, was created to address the need of capturing critical fetal biometric data and remote monitoring of pregnant women at home.
Mayo Clinic selected Medically Home, a Boston-based technology-enabled services company, as its implementation partner for a new care model for delivering innovative, comprehensive, and complex care to patients from the comfort of home. Through this initiative, patients with conditions previously managed in a hospital have the option to transition to a home setting and receive compassionate, high-quality virtual and in-person care and recovery services.
Read more
Mayo Clinic entered into a know-how license agreement with MediView XR Inc., a clinical augmented reality (AR) med-tech company, to advance procedural AR solutions, specifically for surgical procedures in non-fixed, soft tissue/organ or bone planning, navigation or assistance.
Read more
Moat Biotechnology is a clinical stage company focused on the development of novel intranasal and oral vaccines based on a platform (SC-AdVax) exclusively licensed from Mayo Clinic.
Read more
Mayo Clinic entered into a technology development and licensing collaboration with Mustang Bio, a clinical-stage biopharmaceutical company, to develop a novel cell therapy technology to transform the administration of chimeric antigen receptor engineered T cell (“CAR T”) therapies to potentially be used as an off-the-shelf therapy.
Read more
Mayo Clinic selected nference, a Cambridge-based AI company, to provide de-identification capabilities and to serve as a Platform partner to focus on identifying targets for new drugs or new indications for existing drugs. This initiative seeks to accelerate new treatments for diseases and will optimize clinical trials. nference will combine its proprietary knowledge synthesis platform with the clinical expertise of Mayo Clinic physicians and scientists.
Read more
Mayo Clinic collaborated with venture capital firm Eclipse Ventures to found Nucleus RadioPharma, a new company (CDMO) built to ensure cancer patients can access potentially lifesaving radiopharmaceuticals.
Read more
Mayo Clinic is collaborating with Ordr, a software security company, to utilize its platform for IoT security and risk-reduction services critical to the patient care experience.
Based on promising results in early clinical trials, Mayo Clinic entered into an exclusive license agreement with Sorrento Therapeutics to lead the development of an antibody-drug conjugate platform for treating a spectrum of cancers.
Read more
Mayo Clinic entered into an agreement with Theator, a leader in surgical video AI, to utilize its surgical intelligence platform for surgery preparation, performance, and review using contextual insights while maintaining patient privacy. This includes analysis and feedback for intraoperative events, situational awareness, decision-support, competency assessment, teaching moments, and comparative analytics.
Read more
Mayo Clinic entered into a collaboration with TripleBlind for data analysis, algorithm training and validation on one-way encrypted data and next-generation algorithm sharing. Mayo Clinic researchers are testing TripleBlind’s tools on encrypted algorithms on encrypted data ensuring state-of-the-art privacy and security.
Read more
Unity Biotechnology, a start-up cofounded by Mayo Clinic, is developing a new class of therapeutics intended to selectively eliminate or modulate senescent cells to halt, slow or reverse age-related disease and restore tissue to a more functionally healthy state.
Read more
Mayo Clinic and WuXi Diagnostics, a pharmaceutical, biopharmaceutical, and medical device platform company, entered into a strategic collaboration in 2018 to co-develop and deliver clinical diagnostic services in China to accelerate the development of novel esoteric tests. WuXi Diagnostics has since opened its first U.S.-based research and diagnostic testing development facility within the One Discovery Square building located in Rochester, MN to further its collaborative work with Mayo Clinic.
Content displayed is subject to change.